tiprankstipranks
Advertisement
Advertisement
John Newman Reiterates Buy on BridgeBio Oncology Therapeutics, Sets $23 Price Target on Differentiated KRAS G12C Profile
PremiumRatingsJohn Newman Reiterates Buy on BridgeBio Oncology Therapeutics, Sets $23 Price Target on Differentiated KRAS G12C Profile
2M ago
BridgeBio Oncology’s New ERP Rollout Poses Significant Operational and Reporting Risks
Premium
Company Announcements
BridgeBio Oncology’s New ERP Rollout Poses Significant Operational and Reporting Risks
2M ago
BridgeBio Oncology reports Q1 net loss ($42.1M) vs. ($22.1M) last year
Premium
The Fly
BridgeBio Oncology reports Q1 net loss ($42.1M) vs. ($22.1M) last year
3M ago
BridgeBio Oncology appoints Pedro Beltran as CEO, Idan Elmelech as COO
PremiumThe FlyBridgeBio Oncology appoints Pedro Beltran as CEO, Idan Elmelech as COO
3M ago
BridgeBio Oncology announces FDA Fast Track Designation for BBO-11818
Premium
The Fly
BridgeBio Oncology announces FDA Fast Track Designation for BBO-11818
3M ago
3 Best Stocks to Buy Today, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Today, According to Top Analysts
4M ago
BridgeBio Oncology initiated with an Outperform at Raymond James
PremiumThe FlyBridgeBio Oncology initiated with an Outperform at Raymond James
7M ago
BridgeBio Oncology price target lowered to $18 from $20 at Morgan Stanley
Premium
The Fly
BridgeBio Oncology price target lowered to $18 from $20 at Morgan Stanley
7M ago
Reaffirming Buy on BridgeBio Oncology: Differentiated KRASG12C Profile, Strong Early Efficacy, and Broad Keytruda Combination Potential
Premium
Ratings
Reaffirming Buy on BridgeBio Oncology: Differentiated KRASG12C Profile, Strong Early Efficacy, and Broad Keytruda Combination Potential
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100